Investigation Of Transcutaneous Auricular Vagus Nerve Stimulation Efficacy In Female Fibromyalgia Patients
Launched by FENERBAHCE UNIVERSITY · Mar 6, 2025
Trial Information
Current as of April 26, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Female volunteer participants
- • Aged 18-45 with regular menstrual cycles
- • Diagnosed with FMS (Widespread Pain Index≥ 17
- • Symptom Severity Scale≥ 21) according to the 2013 ACR diagnostic criteria by a specialist physician.
- Exclusion Criteria:
- • Neurological deficits,
- • Diabetes
- • Neuropathic disorders
- • Chronic inflammation
- • Immune deficiencies
- • Cardiac diseases
- • Pregnancy
- • Being in the perimenopausal or postmenopausal stages,
- • Menstrual cycles of less than 28 days,
- • Started new medication within the last 3 months,
- • Modifications to their existing treatment apart from taVNS.
About Fenerbahce University
Fenerbahçe University is a distinguished academic institution dedicated to advancing healthcare research through innovative clinical trials. Committed to fostering scientific excellence and interdisciplinary collaboration, the university aims to enhance patient outcomes and contribute to the broader medical community. With a focus on rigorous methodologies and ethical standards, Fenerbahçe University leverages its state-of-the-art facilities and expert faculty to conduct groundbreaking research that addresses critical health challenges and promotes evidence-based practices. Through its clinical trial initiatives, the university strives to translate research findings into tangible benefits for patients and society at large.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Istanbul, , Turkey
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported